Spots Global Cancer Trial Database for Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Intralesional Versus Intramuscular Methotrexate for Non-melanoma Skin Cancers
Official Title: Intralesional Methotrexate Versus Intramuscular Methotrexate in the Treatment of Non-melanoma Skin Cancers
Study ID: NCT05315128
Conditions
Interventions
Study Description
Brief Summary: to compare the effectiveness and safety of intralesional vs. systemic MTX in NMSC management
Detailed Description: Intralesional methotrexate (MTX) could to be promising conservative alternative for non-melanoma skin cancer (NMSC). Systemic MTX was attempted as adjuvant for locally-advanced NMSC.
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Zagazig university, Zagazig, Sharkia, Egypt
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
